Abstract
Recently, the addition of cis-platinum to combination chemotherapy has resulted in an improved complete response rate as compared to combination regimens which do not include platinum (40% vs. 19%, respectively) [1] Unfortunately, the reported follow-up of patients treated with platinum-containing combination chemotherapies is generally less than five years [2–6] (Table 1). It is clear from these results that a substantial portion of the complete remitters after combination chemotherapy will fail after three or more years of follow-up. These patients obviously had undetected microscopic disease which was resistant to chemotherapy.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Neijt JP, Ten Bokkel Huinink WM, van der Burg MEL, van Oosterom AT, Vriesendorp R, Boven E, Kooyman CD, van Honurelingen JC, Pinedo HM: Combination chemotherapy with hexa-CAF and CHAP-5 in advanced ovarian carcinoma: A randomized study of the Netherlands joint study group for ovarian cancer. Proc ASCO 2:148, 1983.
Barker GH, Wiltshaw E: Randomized trial comparing low-dose cis-platin and chlorambucil with low-dose cis-platin, chlorambucil and doxorubicin in advanced ovarian carcinoma. Lancet i: 747–750, 1981.
Williams CJ, Mead B, Arnold A, Green J, Buchanan R, Whitehouse M: Chemotherapy of advanced ovarian carcinoma: initial experience using a platinum-based combination. Cancer 49:1778–1783, 1982.
Young RC, Chabner BA, Hubbard SP, Fisher RI, Bender RA, Anderson T, Simon RM, Canellos GP, DeVita VT: Advanced ovarian adenocarcinoma; A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. New Engl J Med 293:1261–1266, 1978.
Stehman FB, Ehrlich CE, Einhorn LH, Williams SD, Roth LM: Long-term follow-up and survival in Stage III–IV epithelial ovarian cancer treated with cis-dichlorodiammine platinum, adriamycin and cyclosphamide (PAC). Proc ASCO 2:147, 1983.
Greco A: Personal communication.
Van der Schueren E, Van der Bogaert W, Gonzales D: Role of radiotherapy in the treatment of ovarian carcinoma. In: Ovarian Cancer; Advances in the Biosciences, Vol 26. Edited by CE Newman, CHJ Ford, JA Jordan. Pergamon Press, New York 1980, pp 151–164.
Dembo AJ, Bush RS, Beale FA, Bean HA, Pringle JF, Sturgeon JFG: The Princess Margaret Hospital Study of ovarian Cancer: Stage I, II and Asymptomatic III presentations. Cancer Treat Rep 63:249–254, 1979.
Dembo AJ, Bush RS, Beale FA, Bean HA, Fine S, Gospodarowicz M, Herman J, Pringle JF, Sturgeon J, Thomas GM: A ramdomized clinical trial of moving-strip versus open field whole-abdominal irradiation in patients with invasive epithelial cancer of ovary. Proc ASCO 2:146, 1983.
Dembo A: Personal communication.
Skipper HE: Southern Research Institute, Booklet 4 (1980).
Griffiths CT, Fuller AF: Intensive surgical and chemotherapeutic management of advanced ovarian cancer. Surg Clin North Am 58:131–142, 1978.
Smith JP: Surgery for ovarian cancer. In: Newman CE, Ford CHJ, Jordan JA (eds) Ovarian Cancer, Advances in the Biosciences, Vol 26: Pergamon Press, New York, 1980, pp 137–149.
Goldie JH, Coldman AJ: A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63:1727–1733, 1979.
Tattersall MHN, Jarman M, Newlands ES: Pharmaco-kinetics of melphalan following oral or intravenous administtration in patients with malignant disease. Eur J Cancer 14:507–513, 1978.
Alberts DS, Chen HSG, Benz D, Mason NL: Effect of renal dysfunction in dogs on the disposition and marrow toxicity of melphalan. Br J Cancer 43:330–334, 1981.
Fuks Z: Patterns of spread of ovarian carcinoma: relation to therapeutic strategies. In: Newman CE, Ford CHJ, Jordan JA (eds) Ovarian Cancer. Pergamon Press, Oxford, New York, 1980, pp 39–56.
Tak WK, Costanza ME, Marchant DJ, Munzenrider JE, Mitchell GW, Nathanson L, Emami B: Surgery, chemotherapy and supervoltage radiotherapy for carcinoma of the ovary. Int J Radiation Oncology Biol Phys 2:895–901, 1977.
Brady LW, Homesley HD, Blessing JA, Lewis GC, Slayton RE, for the GOG: Radiotherapy (RT), chemotherapy (CT), and combined therapy in Stage III epithelial ovarian cancer. Cancer Clin Trials 1:111–120, 1979.
Fuks Z, Rizel S, Anteby SO, Biran S: The multimodal approach to the treatment of Stage III ovarian carcinoma. Int J Radiation Oncol Biol Phys 8:903–908, 1982.
Pino y Torres JL, Bross DS, Hernandez E, Rosendhein N, Bross DS, Klein JL, Ettinger DS, Leichner PK, Order SE: Multimodality treatment of patients with advanced ovarian carcinoma. Int J Radiation Oncol Biol Phys 8:1671–1677, 1982.
Nevin JE, Pinzon G, Baggerly TJ, Turner FG, Marsella JJ: The use of intravenous phenylalanine mustard followed by supervoltage irradiation in the treatment of carcinoma of the ovary. Cancer 51:1273–1283, 1983.
Hainsworth JB, Malcolm A, Johnson DH, Burnett LS, Jones HW, Greco FA: Advanced minimal residual ovarian carcinoma: abdominopelvic irradiation following combination chemotherapy. Obst Gynecol 61:619–621, 1983.
Vogl SE, Seltzer V, Greenwald E, Kaplan B, Abitbol A: Consolidation radiatherapy and chemotherapy (CT) for ovarian cancer after CT-induced remission: long-term remission of initial bulky disease. Proc ASCO 2:151, 1983.
Greiner R, Goldhirsch A, Dreher E, Davis B, Locher G, Payer T, Neuenschwander H, Joss R, Brunner K, Veraguth P: Whole abdominal radiation in patients with advanced ovarian carcinoma after surgery, chemotherapy and second-look laparotomy. J Cancer Res Clin Oncol 107:94–98, 1984.
Davis B, Goldhirsch A, Locher G, Dreher E, Greiner R, Brunner K: Prognostic factors for remission induction in advanced ovarian cancer. J Cancer Res Clin Oncol 107:106–110, 1984.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1985 Martinus Nijhoff Publishers, Boston
About this chapter
Cite this chapter
Goldhirsch, A., Greiner, R., Davis, B. (1985). Chemotherapy followed by whole-abdominal radiation therapy for ovarian cancer. In: Alberts, D.S., Surwit, E.A. (eds) Ovarian Cancer. Cancer Treatment and Research, vol 23. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2561-1_10
Download citation
DOI: https://doi.org/10.1007/978-1-4613-2561-1_10
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-9609-6
Online ISBN: 978-1-4613-2561-1
eBook Packages: Springer Book Archive